Get the Stockscreener App
1.03
1.98%
0.02
After Hours:
1.03
Xortx Therapeutics Inc Stock (XRTX) Latest News
XORTX Announces Update for Discussion with the FDA - GlobeNewswire
XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks
XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com
XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan
Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News
XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks
XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire
Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com
XORTX to Present at Microcap Conference - GlobeNewswire
XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks
Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - TipRanks
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel
XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks
XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire
XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan
XORTX appoints finance veteran as its new CFO - MSN
XORTX Therapeutics Welcomes New CFO Dr. Bumby - TipRanks
XORTX Strengthens Executive Team - The Manila Times
XORTX Therapeutics Taps Former Eli Lilly Veteran Dr. Michael Bumby as New CFO - StockTitan
XORTX Therapeutics Unveils New Kidney Disease Discoveries - TipRanks
XORTX Announces Presentation at the Rare and Genetic Disease Summit - GlobeNewswire
XORTX Therapeutics Unveils Breakthrough ADPKD Research: Genetic Factors Key to Disease Progression - StockTitan
XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks
XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 - sharewise
XORTX Highlights Kidney Disease Study at ASN - TipRanks
XORTX Secures $1.5 Million in Latest Offering - TipRanks
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
XORTX Therapeutics stock falls after pricing $1.5M capital raise - MSN
XORTX Therapeutics Announces $1.5 Million Offering - TipRanks
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
0.22%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):